摘要
目的评估沐舒坦梯度计量对急性呼吸窘迫综合征(ARDS)的临床疗效和安全性。方法将36例患者随机分成A、B、C、D组,每组9例,分别予沐舒坦1mg/kg/d、5mg/kg/d、10mg/kg/d、15mg/kg/d,分3次静脉滴注,共7天。用药前、用药3d和7d时测定4组患者间动脉血氧分压(PaO2)、氧合指数(PaO2/FiO2)差异。结果用药前各组间PaO2和PaO2/FiO2无差异;用药3d和7d时PaO2及PaO2/FiO2比较:B组和A组间有显著差异(P<0.05),C、D组和A组间有显著差异(P<0.01),C组与B组间有显著差异(P<0.05),C、D组间无显著差异(P>0.05)。结论沐舒坦对外伤性ARDS患者呼吸功能改善与剂量具有正相关性,但大于10mg/kg/d时,这种相关性可能不明显。
Objective To investigate the effect of difference dose ambroxol on the on the lung function of patients accompanied with ARDS with severe thoracic and lung injury. Methods 36 patients with ARDS were divided randomly into four groups. Patients in group A,B,C,D were treated with ambroxol by 1mg/kg/d, 5mg/kg/d, 10mg/kg/d, 15mg/kg/d respectively for 7 days. The blood gas indexes, PaO2,PaO2/FiO2 in serum were measured before and during treatment after 3days and 7days respectively; and the time of patients stayed...
